Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Mohammed Snober, Richard Syzdlo, PhD, Jane Apperley, MB ChB MD, Aristeidis Chaidos, MD PhD, Edward Kanfer, PhD, Dragana Milojkovic, MBBS, PhD, Eduardo Olavarria, MD PhD, Renuka Palanicawandar, MD MRCP, FRCPath, Jiri Pavlu, MD MRCP, FRCPath, Jeannie F Todd, PhD, Nina Salooja, MD

Blood (2018) 132 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2018-99-114229

Published: 2018

Journal Articles

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk

Andrew James Innes, PhD FRCPath, MRCP, Philippa Woolley, MRCP, MBBS, Richard Szydlo, PhD, Sara Lozano, Fiona Fernando, MBChB, Divya Bansal, Renuka Palanicawandar, MD MRCP,FRCPath, Elisabet Nadal-Melsio, MD, Eva Yebra-Fernandez, MD, Jane Apperley, MB ChB MD, Eduardo Olavarria, MD PhD, Jiri Pavlu, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2018-99-117311

Published: 2018

Journal Articles

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Philippa Woolley, MRCP, MBBS, David Slade, Richard Syzdlo, PhD, George Nasry Nesr, MB BCh, Simone Claudiani, MD, Irene Caballes, RN, Fiona Fernando, MBChB, Jiri Pavlu, MD MRCP, FRCPath, Renuka Palani, MD, Edward Kanfer, FRCP, Eduardo Olavarria, MD PhD, Dragana Milojkovic, MBBS, PhD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 5746.

https://doi.org/10.1182/blood-2018-99-114420

Published: 2018

Journal Articles

Safety and Clinical Activity of Combined Romidepsin and Azacitidine Therapy in High Risk Acute Myeloid Leukemia: Preliminary Results of the Romaza Trial

Charles Craddock, Eleni Tholouli, MD PhD, Samuel Munoz Vicente, MSc, Emmanouela Gbandi, BSc, MSc, MScM, PhD, Aimee E Houlton, BSc, MSc, Mark W Drummond, MB ChB, PhD FRCPath, Jiri Pavlu, MD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath

Blood (2017) 130 (Supplement 1): 2581.

https://doi.org/10.1182/blood.V130.Suppl_1.2581.2581

Published: 2017

Journal Articles

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Blood (2016) 128 (22): 5987.

https://doi.org/10.1182/blood.V128.22.5987.5987

Published: 2016

Journal Articles

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Kiran Tawana, MD, Aline Renneville, Jun Wang, PhD, Panayiotis Georgiades, Xavier Thomas, MD, Valerie Mialou, MD, Aleksander Savic, MD, Frederik W Van Delft, MD PhD, Jennifer G. Treleaven, MD, Sameena Iqbal, Norio Asou, MD, PhD, Naokuni Uike, MD, Konstanze Döhner, MD, Lars Bullinger, MD, PhD, Matthias Stelljes, MD, Csaba Bödör, PhD, James D. Cavenagh, MD, Doris Steinemann, PhD, Tim Ripperger, MD, Brigitte Schlegelberger, MD, PhD, Peter Vandenberghe, MD, PhD, Anne Uyttebroeck, MD, Josep F. Nomdedeu, MD, Henrik Hjorth-Hansen, MD, PhD, Rosemary E Gale, PhD, Cynthia L. Toze, MD, FRCP(C), Michael J. Barnett, BMBS, FRCPC, FRCP, FRCPath, Marianna Zombori, MD, Krisztian Kallay, MD, Jiri Pavlu, MD, Pim Mutsaers, MD, Fred H Menko, MD, Angela Thomas, PhD, FRCPath, FRCP, MB, BS, Christine Wright, MD, Jessica Okosun, MD, Chey Loveday, PhD, Pierre Fenaux, MD, PhD, Hamish Scott, PhD, Claude Preudhomme, Claude Chelala, PhD, Alison Male, MD, Carolyn J. Owen, MD, FRCPC, Matthew Smith, MD, PhD, Jude Fitzgibbon, PhD

Blood (2013) 122 (21): 740.

https://doi.org/10.1182/blood.V122.21.740.740

Published: 2013

Journal Articles

Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia

Ailsa Holroyd, MD, Elizabeth Phillips, MD, Richard Szydlo, PhD, David Marin, MD, PhD, Letizia Foroni, MD, PhD, Jamshid Khorashad, MD, PhD, Dragana Milojkovic, MD, PhD, Edward J. Kanfer, MD, Francesco Dazzi, Donald H. MacDonald, MD, PhD, Amin Rahemtulla, MBBS, PhD, FRCP, Donal McLornan, MD, PhD, Ian H Gabriel, MD, Jiri Pavlu, MD, Jeremy Sargent, MD, John M. Goldman, MD, PhD, Jane F. Apperley, MD, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 3515.

https://doi.org/10.1182/blood.V116.21.3515.3515

Published: 2010

NARROW

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Safety and Clinical Activity of Combined Romidepsin and Azacitidine Therapy in High Risk Acute Myeloid Leukemia: Preliminary Results of the Romaza Trial

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Safety and Clinical Activity of Combined Romidepsin and Azacitidine Therapy in High Risk Acute Myeloid Leukemia: Preliminary Results of the Romaza Trial

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only